LVTX

LAVA Therapeutics NV

Sep 18 • 04:00PM ET

1.47

-0.03 -2.00 %

Healthcare • Biotechnology • Netherlands • NASD

Peers: TGTX ADAP AFMD PDSB TVRD AUPH MTEM IMTX HOOK ONCT

Index	-	P/E	-	EPS (ttm)	-1.05	Insider Own	50.16%	Shs Outstand	26.31M	Perf Week	-4.55%
Market Cap	38.67M	Forward P/E	-	EPS next Y	-0.54	Insider Trans	-11.32%	Shs Float	13.11M	Perf Month	-3.61%
Enterprise Value	-17.50M	PEG	-	EPS next Q	-0.24	Inst Own	18.94%	Short Float	0.68%	Perf Quarter	9.70%
Income	-28.29M	P/S	7.75	EPS this Y	-47.41%	Inst Trans	0.31%	Short Ratio	0.67	Perf Half Y	11.36%
Sales	4.99M	P/B	1.94	EPS next Y	61.26%	ROA	-37.02%	Short Interest	0.09M	Perf YTD	54.57%
Book/sh	0.76	P/C	0.69	EPS next 5Y	24.31%	ROE	-90.07%	52W High	2.09 -29.77%	Perf Year	-14.34%
Cash/sh	2.14	P/FCF	-	EPS past 3/5Y	24.14% 81.88%	ROIC	-141.90%	52W Low	0.85 72.90%	Perf 3Y	-40.24%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	30.84% -	Gross Margin	123.29%	Volatility	3.88% 2.61%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-3.51	EPS Y/Y TTM	-15.83%	Oper. Margin	-610.66%	ATR (14)	0.05	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.78	Sales Y/Y TTM	-32.55%	Profit Margin	-566.89%	RSI (14)	38.60	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	10.78	EPS Q/Q	-3.85%	SMA20	-4.61%	Beta	0.49	Target Price	1.37
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-2.01%	Rel Volume	9.87	Prev Close	1.50
Employees	34	LT Debt/Eq	0.00	Earnings	Aug 13 AMC	SMA200	14.48%	Avg Volume	132.81K	Price	1.47
IPO	Mar 25, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-24.66% -	Trades		Volume	1,136,127	Change	-2.00%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-12-24	Downgrade	Leerink Partners	Outperform → Market Perform	$11 → $2
Dec-11-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Oct-25-22	Initiated	H.C. Wainwright	Buy	$9
Apr-19-21	Initiated	SVB Leerink	Outperform	$26
Apr-19-21	Initiated	JP Morgan	Overweight	$22
Apr-19-21	Initiated	Jefferies	Buy	$23

Aug-13-25 04:55PM	LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
07:30AM	XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements (GlobeNewswire)
Aug-04-25 08:15AM	Xoma strikes deals to buy struggling biotechs HilleVax, Lava (BioPharma Dive)
07:30AM	XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right (GlobeNewswire)
May-14-25 07:30AM	LAVA Reports First Quarter 2025 Financial Results, Provides Business Update (GlobeNewswire)
07:30AM	Loading…
Apr-16-25 07:30AM	LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation (GlobeNewswire) +7.89%
Mar-28-25 07:30AM	LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-25-25 07:00AM	LAVA Announces Evaluation of Strategic Options (GlobeNewswire) +42.55%
Jan-10-25 08:23AM	LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers (GlobeNewswire)
Dec-10-24 07:30AM	LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027 (GlobeNewswire) -23.82%
Sep-03-24 08:00AM	LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -10.29%
Aug-20-24 12:53PM	LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024 (InvestorPlace)
07:30AM	LAVA Reports Second Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Jun-20-24 07:30AM	LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference (GlobeNewswire)
Jun-10-24 07:00AM	LAVA Announces Annual Meeting of Shareholders (GlobeNewswire)
07:00AM	Loading…
May-30-24 07:00AM	LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-21-24 01:52PM	LVTX Stock Earnings: LAVA Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:00AM	LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-06-24 04:05PM	LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference (GlobeNewswire) -6.27% +5.63%
Mar-20-24 12:52PM	LVTX Stock Earnings: LAVA Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
07:00AM	LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results (GlobeNewswire)
Mar-05-24 08:30AM	Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments (GlobeNewswire) -25.74%
07:30AM	LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223) (GlobeNewswire)
Jan-25-24 07:00AM	LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA (GlobeNewswire) +42.95%
Nov-16-23 07:00AM	Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Sep-06-23 07:11AM	LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -5.86%
Aug-22-23 07:00AM	LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-14-23 07:00AM	LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference (GlobeNewswire) +9.76%
Jun-14-23 09:00AM	LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway (GlobeNewswire) -9.66%
Jun-08-23 07:00AM	LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results (GlobeNewswire) +16.07%
04:20PM	Loading…
Jun-01-23 04:20PM	LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development (GlobeNewswire) +36.84%
08:09AM	LAVA Therapeutics to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-30-23 05:28PM	LAVA Announces Annual Meeting of Shareholders (GlobeNewswire)
Apr-11-23 07:00AM	LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results (GlobeNewswire)
Mar-09-23 08:05AM	LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors (GlobeNewswire) -7.08%
Feb-16-23 07:00AM	LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium (GlobeNewswire) -20.24%
Feb-09-23 07:00AM	LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference (GlobeNewswire)
Feb-06-23 07:00AM	LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer (GlobeNewswire)
Jan-23-23 07:00AM	LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium (GlobeNewswire)
Jan-06-23 01:07PM	LAVA Therapeutics Announces Appointment of New Directors to the Board (GlobeNewswire)
Jan-03-23 07:00AM	LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-10-22 10:00AM	LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition (GlobeNewswire)
Nov-16-22 04:05PM	LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results (GlobeNewswire) -10.11%
Nov-03-22 04:05PM	LAVA Therapeutics to Present at the Jefferies London Healthcare Conference (GlobeNewswire) +6.99%
09:00AM	LAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition (GlobeNewswire)
Nov-01-22 07:00AM	LAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officer (GlobeNewswire)
Oct-07-22 11:00AM	LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting (GlobeNewswire)
Sep-26-22 08:00AM	Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors (Business Wire) +97.50%
Sep-13-22 04:05PM	LAVA Therapeutics Provides Business Update and Reports Second Quarter Financial Results (GlobeNewswire)
Sep-07-22 07:41AM	LAVA Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Jun-16-22 04:05PM	LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients (GlobeNewswire) -6.67% -14.29%
Jun-15-22 07:00AM	LAVA Therapeutics Announces Two Appointments to its Board of Directors (GlobeNewswire) +6.94%
Jun-02-22 07:00AM	LAVA Therapeutics to Participate at the Jefferies Healthcare Conference (GlobeNewswire)
Jun-01-22 07:00AM	LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-31-22 04:05PM	LAVA Therapeutics Announces Annual Meeting of Shareholders (GlobeNewswire) +5.26%
May-17-22 07:00AM	LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results (GlobeNewswire) -6.04%
May-12-22 07:00AM	LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematologic Malignancies (GlobeNewswire) +13.70%
May-05-22 03:44PM	Investors in LAVA Therapeutics (NASDAQ:LVTX) have unfortunately lost 67% over the last year (Simply Wall St.)
07:00AM	LAVA Therapeutics to Participate at the UBS Global Healthcare Conference (GlobeNewswire)
Apr-27-22 10:05AM	LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Mar-24-22 06:30AM	LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results (GlobeNewswire)
Mar-22-22 05:20PM	How Much Of LAVA Therapeutics N.V. (NASDAQ:LVTX) Do Institutions Own? (Simply Wall St.)
Mar-10-22 06:30AM	LAVA Therapeutics To Present at the Oppenheimer 32nd Annual Healthcare Conference 2022 (GlobeNewswire)
Mar-07-22 08:35AM	LAVA Therapeutics Presents Initial LAVA-051 Clinical Data at the ESMO Targeted Anticancer Therapies Congress 2022 (GlobeNewswire)
Feb-01-22 06:30AM	LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-1207 for Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire) +6.16%
Jan-28-22 07:00AM	Lava Therapeutics Announces Participation in the SVB Leerink 11th Annual Global Healthcare Conference 2022 (GlobeNewswire)
Jan-18-22 08:30AM	LAVA Therapeutics Presents Preclinical Data on its Gammabody T Cell Engager Platform at the 21st Annual PepTalk Conference (GlobeNewswire)
Dec-20-21 10:06AM	CORRECTING AND REPLACING - LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
07:00AM	LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-15-21 07:00AM	LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results (GlobeNewswire)
Nov-11-21 12:16PM	Q&A: CEO Stephen Hurly explains why Lava Therapeutics chose Philadelphia over Boston (American City Business Journals)
10:08AM	LAVA Therapeutics and The Antibody Society Present Emerging Cancer Therapies Virtual Symposium (GlobeNewswire)
Nov-09-21 06:30AM	LAVA Therapeutics Expands Management Team with Three Key Appointments (GlobeNewswire)
Nov-04-21 07:00AM	LAVA Therapeutics to Participate in the 12th Annual Jefferies London Healthcare Conference (GlobeNewswire)
Nov-02-21 07:00AM	LAVA Therapeutics Announces Participation at Upcoming Scientific Conferences (GlobeNewswire)
Oct-15-21 07:00AM	LAVA Therapeutics Receives FDA Orphan Drug Designation for LAVA-051 for the Treatment of Chronic Lymphocytic Leukemia (GlobeNewswire) -6.55%
Oct-07-21 12:36PM	CORRECTING and REPLACING: LAVA Therapeutics to Present its Bispecific Gamma Delta T Cell Engagers for Treatment of Cancer at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
11:31AM	LAVA Therapeutics to Present its Bispecific Gamma Delta T Cell Engagers for Treatment of Cancer at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-23-21 10:26AM	Could The Lava Therapeutics B.V. (NASDAQ:LVTX) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
Aug-16-21 07:05AM	LAVA Therapeutics Provides Business Update and Reports Second Quarter Results (GlobeNewswire)
Jul-27-21 08:00AM	LAVA Therapeutics Announces Appointment of Amy Garabedian as General Counsel and Corporate Secretary (GlobeNewswire) +8.70%
Jul-13-21 07:00AM	LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematological Malignancies (GlobeNewswire)
May-25-21 06:30AM	LAVA Therapeutics to Present at 2021 Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-20-21 06:30AM	LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results (GlobeNewswire)
May-18-21 06:30AM	LAVA Therapeutics to Present at 2021 UBS Global Healthcare Virtual Conference (GlobeNewswire)
May-10-21 09:29AM	Buy These 2 New Stocks Before They Jump Over 80%, Says JPMorgan (TipRanks) +12.20%
Apr-01-21 07:54AM	LAVA Therapeutics Appoints Karen J. Wilson to its Board of Directors (GlobeNewswire) -14.42%
Mar-25-21 11:31AM	Gilde Healthcare Announces Successful Pricing of Nasdaq IPO of Portfolio Company, Lava Therapeutics (GlobeNewswire)
Mar-24-21 08:55PM	LAVA Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Versant Venture Capital VI, L.	10% Owner	Sep 17 '25	Sale	1.49	362,806	540,291	2,736,644	Sep 18 06:49 PM
Versant Venture Capital VI, L.	10% Owner	Sep 18 '25	Sale	1.44	366,111	527,859	2,370,533	Sep 18 06:49 PM
Versant Venture Capital VI, L.	10% Owner	Sep 16 '25	Sale	1.53	307,707	471,776	3,099,450	Sep 18 06:49 PM
Versant Venture Capital VI, L.	10% Owner	Sep 17 '25	Sale	1.49	226,726	337,640	761,661	Sep 18 06:49 PM
Versant Venture Capital VI, L.	10% Owner	Sep 18 '25	Sale	1.44	228,791	329,871	532,870	Sep 18 06:49 PM
Versant Venture Capital VI, L.	10% Owner	Sep 16 '25	Sale	1.53	192,293	294,824	988,387	Sep 18 06:49 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LVTX

LAVA Therapeutics NV

Upgrade your FINVIZ experience